Dogwood Therapeutics, Inc. — Form 10-Q
Filed August 14, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 2/100
What the filing says
CEO Greg Duncan and CFO Angela Walsh certified the June 30, 2026 quarterly report on August 14, 2026, confirming accuracy of financial statements, effectiveness of disclosure controls and internal controls over financial reporting, and compliance with Securities Exchange Act requirements. No material changes, deficiencies, or fraud disclosures were reported.
Why this rating
Routine Sarbanes-Oxley certifications with no disclosed control deficiencies, restatements, or changes. Boilerplate compliance filing.
See more from August 14, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.